6.5 Golimumab, 50 mg 0.5 mL injection, 1x 0.5 mL, syringe Simponi®; Infliximab, 100 mg injection, 1x 100 mg vial, Remicade®; Ustekinumab 45 mg 0.5 ml injection, 1x 0.5 ml vial, - Centocor - Document - PDFSEARCH.IO

First Page	Meta Content
	6.5 Golimumab, 50 mg/0.5 mL injection, 1x 0.5 mL, syringe Simponi®; Infliximab, 100 mg injection, 1x 100 mg vial, Remicade®; Ustekinumab 45 mg/0.5 ml injection, 1x 0.5 ml vial, Add to Reading List Document Date: 2015-04-22 23:39:46 Open Document File Size: 176,09 KB Share Result on Facebook Company Janssen-Cilag Pty Ltd / Human Services / / Country Australia / / Facility Consumer Comments facility / / IndustryTerm recommended telephone / written applications / telephone authority / / MedicalCondition severe ulcerative colitis / severe chronic plaque psoriasis / / Organization Department of Human Services / / Product Remicade / / SocialTag Pharmaceutical sciences Immunosuppressants Monoclonal antibodies Ustekinumab Infliximab Golimumab Clinical trial Biologic Psoriasis Centocor

6.5 Golimumab, 50 mg/0.5 mL injection, 1x 0.5 mL, syringe Simponi®; Infliximab, 100 mg injection, 1x 100 mg vial, Remicade®; Ustekinumab 45 mg/0.5 ml injection, 1x 0.5 ml vial,Add to Reading List